Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2021 Sep 14

PMID 34519913

Citations 10

Authors

Michele Correale

Pietro Mazzeo

Adriana Mallardi

Alessandra Leopizzi

Lucia Tricarico

Martino Fortunato

Michele Magnesa

Salvatore Tucci

Pasquale Maiellaro

Giuseppe Pastore

Olga Lamacchia

Massimo Iacoviello

Matteo Di Biase

Natale Daniele Brunetti

Affiliations

Soon will be listed here.

Abstract

Purpose: The use of sodium-glucose-cotransporter-type-2 inhibitors (SGLT2i) was associated in previous studies with an improved vascular function in non-human experimental models. We therefore sought to evaluate possible changes in endothelial function assessed by flow-mediated dilation (FMD) in patients with chronic heart failure (CHF) and type-2 diabetes mellitus (T2DM), switching from other oral hypoglycemic agents to SGLT2i in an observational study.

Methods: Twenty-two consecutive outpatients with CHF and T2DM were enrolled after switching to SGLT2i therapy, and compared with 23 consecutive controls from the same registry comparable for principal clinical characteristics. In all patients, endothelial function was assessed by FMD at baseline and after 3 months of follow-up.

Results: Three months of therapy with SGLT2i were associated with a statistically significant improvement in endothelial function (19.0 ± 5.7% vs 8.5 ± 4.1%, p < 0.0001); baseline levels of FMD were comparable between groups (p n.s.). Therapy with SGLT2i was significantly associated to improved FMD levels even at multivariable stepwise regression analysis (p < 0.001).

Conclusions: Switch to SGLT2i in patients with CHF and T2DM was associated in an observational non-randomized study with an improved endothelial function.

Citing Articles

Impact of sodium-glucose cotransporter inhibitors in acute coronary syndrome patients on endothelial function and atherosclerosis related-biomarkers: ATH-SGLT2i pilot study.

Mghaieth Zghal F, Abbassi M, Silini A, Ben Halima M, Jebberi Z, Daly F Medicine (Baltimore). 2025; 103(47):e40536.

PMID: 39813066 PMC: 11596703. DOI: 10.1097/MD.0000000000040536.

The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives-A Narrative Review.

Miceli G, Basso M, Pennacchio A, Cocciola E, Pintus C, Cuffaro M Medicina (Kaunas). 2024; 60(11).

PMID: 39596981 PMC: 11596194. DOI: 10.3390/medicina60111796.

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus.

Peppa M, Manta A, Mavroeidi I, Asimakopoulou A, Syrigos A, Nastos C Pharmaceutics. 2023; 15(11).

PMID: 38004506 PMC: 10675228. DOI: 10.3390/pharmaceutics15112526.

Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients.

Yanai H, Adachi H, Hakoshima M, Katsuyama H Metabolites. 2023; 13(6).

PMID: 37367894 PMC: 10303074. DOI: 10.3390/metabo13060736.

SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century?.

Correale M, Tricarico L, Iacoviello M, Brunetti N J Clin Med. 2023; 12(7).

PMID: 37048778 PMC: 10095017. DOI: 10.3390/jcm12072695.

References

Neal B, Perkovic V, Matthews D, Mahaffey K, Fulcher G, Meininger G . Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab. 2017; 19(3):387-393. PMC: 5348724. DOI: 10.1111/dom.12829. View

Filippatos T, Liontos A, Papakitsou I, Elisaf M . SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019; 131(2):82-88. DOI: 10.1080/00325481.2019.1581971. View

Juni R, Kuster D, Goebel M, Helmes M, Musters R, van der Velden J . Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. JACC Basic Transl Sci. 2019; 4(5):575-591. PMC: 6872802. DOI: 10.1016/j.jacbts.2019.04.003. View

Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H . Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017; 16(1):84. PMC: 5500953. DOI: 10.1186/s12933-017-0564-0. View

Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R . Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol. 2021; 20(1):74. PMC: 8004411. DOI: 10.1186/s12933-021-01264-z. View

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018; 200:83-89. DOI: 10.1016/j.ahj.2018.01.012. View

Lee D, Battson M, Jarrell D, Hou S, Ecton K, Weir T . SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018; 17(1):62. PMC: 5921754. DOI: 10.1186/s12933-018-0708-x. View

Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H . Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017; 16(1):48. PMC: 5389095. DOI: 10.1186/s12933-017-0532-8. View

10.

Maulucci G, Cipriani F, Russo D, Casavecchia G, Di Staso C, Di Martino L . Improved endothelial function after short-term therapy with evolocumab. J Clin Lipidol. 2018; 12(3):669-673. DOI: 10.1016/j.jacl.2018.02.004. View

11.

Solini A, Giannini L, Seghieri M, Vitolo E, Taddei S, Ghiadoni L . Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017; 16(1):138. PMC: 5654086. DOI: 10.1186/s12933-017-0621-8. View

12.

Gaspari T, Spizzo I, Liu H, Hu Y, Simpson R, Widdop R . Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2017; 15(1):64-73. DOI: 10.1177/1479164117733626. View

13.

Correale M, Leopizzi A, Mallardi A, Ranieri A, Suriano M, DAlessandro D . Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation. Thromb Res. 2020; 195:16-20. DOI: 10.1016/j.thromres.2020.06.046. View

14.

Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39(2):257-65. DOI: 10.1016/s0735-1097(01)01746-6. View

15.

Irace C, Casciaro F, Scavelli F, Oliverio R, Cutruzzola A, Cortese C . Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. Cardiovasc Diabetol. 2018; 17(1):52. PMC: 5891980. DOI: 10.1186/s12933-018-0695-y. View

16.

Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R . Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose.... Circulation. 2017; 136(3):249-259. PMC: 5515629. DOI: 10.1161/CIRCULATIONAHA.117.029190. View

17.

Salim H, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M . Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Front Cardiovasc Med. 2016; 3:43. PMC: 5080286. DOI: 10.3389/fcvm.2016.00043. View

18.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

19.

Oelze M, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Mikhed Y . The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014; 9(11):e112394. PMC: 4234367. DOI: 10.1371/journal.pone.0112394. View

20.

Scheen A . Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Curr Cardiol Rep. 2019; 21(8):70. DOI: 10.1007/s11886-019-1165-1. View